Supplementary Figures S1-S8 from Improved Treatment of Breast Cancer with Anti-HER2 Therapy Requires Interleukin-21 Signaling in CD8<sup>+</sup> T Cells

IL-21R expression on splenocytes and TILs from H2N100 tumor-bearing mice (S1); ErbB-2 positive tumor cell lines do not express IL-21R (S2); CD8+ T cells and NK cells after ACT in Balb/c.Rag2-/- γc-/- mice (S3); B-cells and NKT cells are not likely to be required for anti-ErbB-2 mAb therapy (S4); Tfh cells are not likely to be required for anti-ErbB-2 mAb therapy (S5); Myeloid cell infiltrates in ErbB-2+ tumors (S6); Recombinant IL-21 improves therapeutic efficacy of anti-ErbB-2 mAb therapy (S7); Spearmans' correlations are shown between genes of interest, TILs as previously described and selected genes representing CD8+ T cell phenotype using patient's samples from the FinHER clinical trial (S8).